ストックスクリーナーアプリを入手
33.54
1.45%
0.48
プレマーケット:
33.95
0.41
+1.22%
Viridian Therapeutics Inc (VRDN) 最新ニュース
Viridian Therapeutics: Cautious Optimism As Key Milestones Approach (Rating Downgrade) - Seeking Alpha
(VRDN) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Pullback Watch: What are Viridian Therapeutics Incs earnings expectationsJuly 2025 Update & Expert-Curated Trade Recommendations - baoquankhu1.vn
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Evercore Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Cuts Target Price to $44 - 富途资讯
Viridian Therapeutics, Inc.'s (NASDAQ:VRDN) Business Is Trailing The Industry But Its Shares Aren't - 富途资讯
Did FDA Priority Review and EU Push for Thyroid Eye Drug Just Shift Viridian Therapeutics' (VRDN) Investment Narrative? - Sahm
SG Americas Securities LLC Acquires 49,981 Shares of Viridian Therapeutics, Inc. $VRDN - MarketBeat
Viridian Therapeutics stock hits 52-week high at $34.06 By Investing.com - Investing.com Nigeria
Responsive Playbooks and the VRDN Inflection - Stock Traders Daily
Viridian Therapeutics stock jumps to a 52-week high as VRDN traders zero in on June FDA deadline - TechStock²
Viridian Therapeutics (NASDAQ:VRDN) Reaches New 52-Week HighStill a Buy? - MarketBeat
Viridian Therapeutics stock hits 52-week high at $34.06 - Investing.com
Market Review: Is Viridian Therapeutics Inc stock a good pick for beginnersPortfolio Return Report & Capital Efficiency Focused Ideas - baoquankhu1.vn
Viridian Therapeutics, Inc. (VRDN): Growth Potential in Biotechnology with an 81,958% Revenue Surge - DirectorsTalk Interviews
Will Viridian Therapeutics Inc. stock continue upward momentumJuly 2025 Decliners & Real-Time Buy Zone Alerts - Улправда
Viridian Therapeutics (NASDAQ:VRDN) Upgraded by UBS Group to "Strong-Buy" Rating - MarketBeat
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)January 8, 2026 - BioSpace
Assessing Viridian Therapeutics (VRDN) Valuation After FDA Priority Review For Veligrotug - Sahm
What MACD trends signal for Viridian Therapeutics Inc. (1S1) stockPortfolio Performance Report & Expert Curated Trade Setup Alerts - ulpravda.ru
Will Viridian Therapeutics Inc. stock continue dividend increasesJuly 2025 Short Interest & Low Drawdown Trading Techniques - ulpravda.ru
Is Viridian Therapeutics Inc. stock attractive after correctionCPI Data & Technical Entry and Exit Alerts - Улправда
How Viridian Therapeutics Inc. stock compares to market leaders2025 Trading Volume Trends & Expert Approved Momentum Ideas - Улправда
Viridian Therapeutics, Inc.Common Stock (NQ: VRDN - FinancialContent
Why CHRO stock attracts strong analyst attention - Улправда
Can Viridian Therapeutics Inc. stock deliver strong Q4 earningsQuarterly Market Review & Real-Time Chart Pattern Alerts - Улправда
VRDN: Truist Securities Lowers Price Target but Maintains Buy Ra - GuruFocus
Viridian Therapeutics (NASDAQ:VRDN) Price Target Lowered to $40.00 at Truist Financial - MarketBeat
Why Viridian Therapeutics Inc. stock is in analyst buy zonePortfolio Gains Report & Smart Investment Allocation Insights - Улправда
UBS Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Raises Target Price to $50 - 富途牛牛
Oklahoma City NewsThe Oklahoman - FinancialContent
UBS Initiates Coverage of Viridian Therapeutics (VRDN) with Buy Recommendation - Nasdaq
Will Viridian Therapeutics Inc. stock deliver consistent dividendsLong-Term Growth Stocks & Turn Market Volatility into Wealth - Улправда
VRDN: UBS Initiates Coverage with a 'Buy' Rating and $50 Price T - GuruFocus
Why Viridian Therapeutics Inc. stock remains resilientHigh Beta Stocks & Outstanding Portfolio Tips - Улправда
Free cash flow per share of Viridian Therapeutics, Inc. – DUS:1S1 - TradingView — Track All Markets
UBS initiates Viridian Therapeutic stock with Buy rating on TED treatment - Investing.com Canada
Jefferies reiterates Buy rating on Viridian Therapeutic stock with $44 target - Investing.com Canada
Viridian Therapeutic stock a Top Pick at TD Cowen ahead of busy 2026 - Investing.com Canada
Viridian Therapeutics Prepares for Transformational 2026 - BioSpace
Viridian Therapeutics, Inc. (VRDN) Investor Outlook: Exploring a Potential 36.59% Upside in the Biotech Arena - DirectorsTalk Interviews
About Us | Laser Focus WorldViridian Therapeutics Prepares for Transformational 2026 - FinancialContent
Entry Recap: Will Viridian Therapeutics Inc. stock outperform international peersMarket Volume Report & Consistent Profit Trading Strategies - ulpravda.ru
Is Viridian Therapeutics Inc. stock positioned for long term growth2026 world cup usa national team qualification midfield engines high defensive line tactical prediction insights - ulpravda.ru
Viridian Therapeutics’ Veligrotug Shows Durable Proptosis Response in Phase 3 TED Trial - MSN
VRDN Stock Price, Forecast & Analysis | VIRIDIAN THERAPEUTICS INC (NASDAQ:VRDN) - Chartmill
What to keep an eye on in 2026 - Eyes On Eyecare
Understanding the Setup: (VRDN) and Scalable Risk - Stock Traders Daily
Viridian Therapeutics (NASDAQ:VRDN) Insider Sells $70,795.52 in Stock - MarketBeat
Insider Sell: Jennifer Tousignant Sells 2,272 Shares of Viridian Therapeutics Inc (VRDN) - GuruFocus
Viridian Therapeutics (VRDN) Chief Legal Officer reports 2,272-share stock sale - Stock Titan
What analysts say about Viridian Therapeutics Inc stockGrowth vs. Value Investing & Low Risk Investment Tips - earlytimes.in
How M&A Unlocked A Biotech Rebound In 2025— And What Comes Next? - Benzinga
Viridian Therapeutics Earnings Notes - Trefis
Simplify Asset Management Inc. Purchases Shares of 50,000 Viridian Therapeutics, Inc. $VRDN - MarketBeat
2.09%
0.48%
大文字化:
|
ボリューム (24 時間):